Optimizing brief, focused symptom assessment in recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN): The FHNSI-10.

被引：1
|
作者：
Shaunfield, Sara
Yount, Susan
Boyken, Lara
Stoykova, Boyka
Agulnik, Mark
Samant, Sandeep
Cella, David
机构：
[1] Northwestern Univ, Chicago, IL 60611 USA
[2] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA
[3] Daiichi Sankyo UK Ltd, Gerrards Cross, London, England
[4] Univ Tennessee, Memphis, TN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.e18743
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e18743
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Optimizing brief, focused assessment of priority symptoms and concerns in recurrent and/or metastatic squamous cell carcinoma of the head and neck: Content validation of the Functional Assessment of Cancer Therapy/National Comprehensive Cancer Network Head and Neck Symptom Index-10 (FHNSI-10)
    Shaunfield, Sara
    Yount, Susan E.
    Boyken, Lara
    Agulnik, Mark
    Samant, Sandeep
    Cella, David
    HEALTH SCIENCE REPORTS, 2021, 4 (04)
  • [2] Optimizing treatments for recurrent or metastatic head and neck squamous cell carcinoma
    Specenier, Pol
    Vermorken, Jan B.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2018, 18 (09) : 901 - 915
  • [3] Optimizing Treatment for Head and Neck Cancers: Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
    Haddad, Robert, I
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2020, 18 (07): : 982 - 984
  • [4] The triplet docetaxel, carboplatin and capecitabine in recurrent or metastatic squamous cell carcinoma of head and neck (SCCHN).
    Kattan, J
    Farhat, F
    Chahine, G
    Nasr, F
    Moukadem, W
    Younes, F
    Ghosn, M
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 521S - 521S
  • [5] Phase II trial of sunitinib in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN)
    Choong, N. W.
    Cohen, E. E.
    Kozloff, M. F.
    Taber, D.
    Wade, J. L., III
    Hu, S.
    Ivy, S. P.
    Nichols, K.
    Dekker, A.
    Vokes, E. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [6] Cetuximab with or without sorafenib in recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN)
    Gilbert, Jill
    Schell, Michael J.
    Zhao, Xiuhua
    Murphy, Barbara A.
    Tanvetyanon, Tawee
    Hayes, David N.
    Haigentz, Missak
    Saba, Nabil F.
    Nieva, Jorge J.
    Perez, Jimena
    Bishop, Justin A.
    Chung, Christine H.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [7] Single Agent Irinotecan for The Treatment of Metastatic or Recurrent Squamous Carcinoma of the Head and Neck (SCCHN)
    Gilbert, J.
    Dang, T.
    Cmelak, A.
    Shyr, Y.
    Netterville, J.
    Burkey, B.
    Chung, C. H.
    Ikpeazu, E.
    Murphy, B. A.
    CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2007, 1 : 59 - 63
  • [8] Phase II study of vinorelbine (NVB) in patients with metastatic and/or recurrent squamous cell carcinoma of the head and neck (SCCHN)
    Degardin, M
    Bastit, P
    Rolland, F
    Armand, JP
    Chevallier, B
    VanGlabbeke, M
    Boudillet, J
    Tresca, P
    EUROPEAN JOURNAL OF CANCER, 1997, 33 : 843 - 843
  • [9] Palliative chemotherapy with cisplatin (C) and ifosfamide (I) for recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN).
    Fernández, A
    Mesía, R
    Montes, A
    Cardenal, F
    Montes, A
    García, M
    Dotor, E
    Muñoz, M
    Juan, A
    Monner, A
    Galiana, R
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S68 - S68
  • [10] Immunotherapy in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
    Hsieh, Ronan W.
    Borson, Steven
    Tsagianni, Anastasia
    Zandberg, Dan P.
    FRONTIERS IN ONCOLOGY, 2021, 11
12345